Experimental models of polycystic ovary syndrome: An update

Divyashree, S.; Janhavi, P.; Ravindra, P. V.; Muthukumar, S. P.

doi:10.1016/j.lfs.2019.116911

Cited by 21 publications

(18 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as far as we know, whether Rhamnocitrin can restore the ovarian damage in PCOS remains unclear. Due to ethical issues, studies on humans have limitations, hence animal models of PCOS aids in studying various aspects beginning from etiology to the treatment [25]. In current study, we rst investigated impacts of Rhamnocitrin on DHEA -induced PCOS rats.…”

Section: Discussionmentioning

confidence: 99%

Rhamnocitrin Ameliorates Ovarian Fibrosis Via PPARγ/TGF-β1/Smad Pathway to Repair Ovarian Function in Polycystic Ovary Syndrome Rats Running Title：rhamnocitrin Ameliorates Ovarian Fibrosis in Polycystic Ovary Syndrome Rats

Zhou

Dong

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Polycystic ovary syndrome (PCOS) is one of the major endocrine disorders in women, characterized by androgen excess, chronic anovulation and ovarian fibrosis. Rhamnocitrin is an herbal bioactive flavonoid that has anti-inflammation and antioxidant effects. We intended to investigate the impacts of Rhamnocitrin on PCOS-induced ovarian fibrosis and its underlying mechanisms.Methods: Dehydroepiandrosterone (DHEA) induced-PCOS rats were treated with Rhamnocitrin. HE staining was performed to detect ovarian histological features. Ovarian fibrosis was evaluated by Sirius Red and Masson staining. Vaginal smear was examined to exhibit estrus cycle stage and vaginal cornification. The serum hormone levels of FSH, LH, E2 and T were measured with ELISA. The related mRNAs and proteins of fibrosis factors and PPARγ/TGF-β1/Smad2 signaling were detected by RT-qPCR and western blot. The weights of rat bodies and ovaries were recorded. PPARγ inhibitor T0070907 and its agonist GW1929 were employed for the mechanistic investigation.Results: The corpus luteum and follicles were increased and irregular estrous cycle was restored after Rhamnocitrin treatment in PCOS rats. Rhamnocitrin inhibited ovarian fibrosis and down-regulated the expressions of fibrotic factors. Rhamnocitrin reduced the increased levels of LH, E2, and T, and elevated the decreased FSH level in PCOS rats. Besides, Rhamnocitrin elevated the down-regulated PPARγ, and suppressed the up-regulated TGF-β1 and p-Smad2 expressions induced by PCOS. These effects of Rhamnocitrin on PCOS rats could be antagonized by T0070907, whereas GW1929 markedly mimics the functions of Rhamnocitrin. Conclusions: Rhamnocitrin ameliorates ovarian fibrosis in PCOS rats through regulation PPARγ/TGF-β1/Smad2pathway, suggesting it can be a potentially effective therapeutic candidate for PCOS treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Rhamnocitrin Ameliorates Ovarian Fibrosis Via PPARγ/TGF-β1/Smad Pathway to Repair Ovarian Function in Polycystic Ovary Syndrome Rats Running Title：rhamnocitrin Ameliorates Ovarian Fibrosis in Polycystic Ovary Syndrome Rats

Zhou

Dong

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, as far as we know, whether Rhamnocitrin can restore the ovarian damage in PCOS remains unclear. Due to ethical issues, studies on humans have limitations, hence animal models of PCOS aids in studying various aspects beginning from etiology to the treatment [20]. In current study, we rst investigate impacts of Rhamnocitrin on DHEA -induced PCOS rats.…”

Section: Discussionmentioning

confidence: 99%

“…PCOS rodent model induced by dehydroepiandrosterone (DHEA) displays critical characteristics similar to PCOS women, including a high androgen state, abnormal secretion of serum hormones, blocked follicular development, de cient corpora lutea and presence of cystic follicles and so on [20]. Furthermore, DHEAinduced PCOS rats are validated to present ovarian collagen deposition and hyper brosis, which compromises ovarian functions [12,21,22].…”

Section: Introductionmentioning

confidence: 99%

Rhamnocitrin ameliorates ovarian fibrosis via PPARγ/TGF-β1/Smad2/3 pathway to repair ovarian function in polycystic ovary syndrome rats

Zhou

Dong

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Polycystic ovary syndrome (PCOS) is one of the major endocrine disorders in women, characterized by androgen excess, chronic anovulation and ovarian fibrosis. Rhamnocitrin is an herbal bioactive flavonoid that has anti-inflammation and antioxidant effects. We intended to investigate the impacts of Rhamnocitrin on PCOS-induced ovarian fibrosis and its underlying mechanisms.Methods:Dehydroepiandrosterone (DHEA) induced-PCOS rats were treated with Rhamnocitrin. HE staining was performed to detect ovarian histological features. Ovarian fibrosis was evaluated by Sirius Red and Masson staining. Vaginal smear was examined to exhibit estrus cycle stage and vaginal cornification. The serum hormone levels of FSH, LH, E2 and T were measured with ELISA. The related mRNAs and proteins of fibrosis factors and PPARγ/TGF-β1/Smad2/3 signaling were detected by RT-qPCR and western blot. The weights of rat bodies and ovaries were recorded. PPARγ inhibitor T0070907 and its agonist GW1929 were employed for the mechanistic investigation.Results:The corpus luteum and follicles were increased and irregular estrous cycle was restored after Rhamnocitrin treatment in PCOS rats. Rhamnocitrin inhibited ovarian fibrosis and down-regulated the expressions of fibrotic factors. Rhamnocitrin reduced the increased levels of LH, E2, and T, and elevated the decreased FSH level in PCOS rats. Besides, Rhamnocitrin elevated the down-regulated PPARγ, and suppressed the up-regulated TGF-β1 and p-Smad2/3 expressions induced by PCOS. These effects of Rhamnocitrin on PCOS rats could be antagonized by T0070907, whereas GW1929 markedly mimics the functions of Rhamnocitrin.Conclusions:Rhamnocitrin ameliorates ovarian fibrosis in PCOS rats through regulation PPARγ/TGF-β1/Smad2/3 pathway, suggesting it can be a potentially effective therapeutic candidate for PCOS treatment.

show abstract

“…as a model for simple hepatic cysts widely used, but they have limitations. For example, their pathogenesis is different from that of simple cysts, their modeling time is long and they have multiple small cysts (13)(14)(15). Thus, such animal models are not suitable for studying percutaneous sclerotherapy of cysts.…”

Section: Time Course Of Histopathological Changes After Bleomycin Sclerotherapy In Rabbit Gallbladdersmentioning

confidence: 99%

Time course of histopathological changes after bleomycin sclerotherapy in rabbit gallbladders as a model for simple hepatic cysts

Lao

Zhang

2021

Biomed Rep

View full text Add to dashboard Cite

Bleomycin sclerotherapy is used in the treatment of cystic lesions; however, the histopathological changes are undefined. Present animal models of cystic diseases are not adequate for the study of sclerotherapy of hepatic cysts, primarily because the established cysts in these models are too small in size. The aim of the present study was to establish a new animal model of simple hepatic cysts, and assess the histopathological changes after bleomycin sclerotherapy. Rabbit gallbladder, with ligaturing of the cholecystic duct whilst preserving cholecystic vessels, was used as a model for simple hepatic cysts. Bleomycin (2 mg dissolved in 1 ml saline) was injected into the aspirated gallbladder, gallbladder tissue was harvested (after 1, 7, 14, 28, 42, 56 and 84 days) and histopathological changes were evaluated (n=4 per group). Additionally, control rabbit gallbladders were injected with 1 ml saline and sampled after 14 days (n=4). Histopathological changes were evaluated using hematoxylin-eosin and Masson's trichrome staining, and immunohistochemistry for CD20-, CD43-and CD68-positive cells was performed. The integrated optical density (IOD) of immunohistochemical staining and average positive stained area percentage (APSAP) of collagen were quantitatively analyzed. The results revealed gallbladders in the control group had regular epithelial cells with no visible inflammation or fibrosis. In the experimental group, epithelial cells were swollen and necrotic on the first day, and were replaced gradually by single-layer flat cells from day 56. Inflammatory infiltration was found in the submucosa, and the IOD of T cells, B cells and macrophages were highest on day 1, and these parameters declined gradually, eventually disappearing. The APSAP of collagen was highest on day 7, and gradually declined thereafter. The results suggest that histopathological changes after bleomycin sclerotherapy of a simple hepatic cyst model were characterized by sequential epithelial destruction, inflammatory cell infiltration, collagen proliferation and epithelial partial regeneration.

show abstract

Experimental models of polycystic ovary syndrome: An update

Cited by 21 publications

References 146 publications

Rhamnocitrin Ameliorates Ovarian Fibrosis Via PPARγ/TGF-β1/Smad Pathway to Repair Ovarian Function in Polycystic Ovary Syndrome Rats Running Title：rhamnocitrin Ameliorates Ovarian Fibrosis in Polycystic Ovary Syndrome Rats

Rhamnocitrin Ameliorates Ovarian Fibrosis Via PPARγ/TGF-β1/Smad Pathway to Repair Ovarian Function in Polycystic Ovary Syndrome Rats Running Title：rhamnocitrin Ameliorates Ovarian Fibrosis in Polycystic Ovary Syndrome Rats

Rhamnocitrin ameliorates ovarian fibrosis via PPARγ/TGF-β1/Smad2/3 pathway to repair ovarian function in polycystic ovary syndrome rats

Time course of histopathological changes after bleomycin sclerotherapy in rabbit gallbladders as a model for simple hepatic cysts

Contact Info

Product

Resources

About